There is no doubt that this deal could add millions to Vuzix bottom line as well as lead to more large contracts. Good day everyone, We are continuing...
Initiating Coverage: Producing Products Conducive to Our New Normal, 166 Patents and Growing
Vuzix (VUZI) Breaks Through Moving Averages in a Bullish Manner Vuzix has grown from 90 patents and patents pending to 166, over the last 36 months Go...
Tremfya (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Article Link: Tremfya (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psori...
FDA Approves Upneeq (oxymetazoline hydrochloride ophthalmic solution) for Acquired Blepharoptosis (Droopy Eyelid) in Adults
Article Link: FDA Approves Upneeq (oxymetazoline hydrochloride ophthalmic solution) for Acquired Blepharoptosis (Droopy Eyelid) in Adults ...
FDA Approves Hulio (adalimumab-fkjp), a Biosimilar to Humira
Article Link: FDA Approves Hulio (adalimumab-fkjp), a Biosimilar to Humira HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 ...
We Have an Exciting New Low Float Report Coming Before 3PM Eastern on 07/16/20
Welcome to all our new group members!!! Your timing is perfect, as we are evaluating 3 separate low float stocks and a “never seen before in our...
Ipsen Announces Updated Indication for Dysport (abobotulinumtoxinA) for the Treatment of Spasticity in Children
Article Link: Ipsen Announces Updated Indication for Dysport (abobotulinumtoxinA) for the Treatment of Spasticity in Children CAMBRIDGE, ...
FDA Approves Expanded Botox (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
Article Link: FDA Approves Expanded Botox (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity NORTH CHICAG...
FDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML)
Article Link: FDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML)...
What You Need to Know About Citius Pharma (NASDAQ: CTXR)
What You Need to Know About Citius Pharma (CTXR) Good day everyone, We are continuing our coverage of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a s...